FDA Class II Drug Recall: TOBRADEX Ophthalmic Ointment, Temperature Abuse
McKesson Medical-Surgical is recalling TOBRADEX ophthalmic ointment nationwide due to cGMP deviations involving temperature abuse. Product distributed between June 1 and September 30, 2021 may be affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II drug recall with cGMP deviations related to temperature abuse. No illnesses, injuries, or hospitalizations have been reported. This meets the Moderate threshold as a manufacturing deviation without reported harm or high-risk contamination.
Plain-English summary
TOBRADEX (tobramycin and dexamethasone) ophthalmic ointment, 3.5 gm, is being recalled nationwide by McKesson Medical-Surgical Inc. The original manufacturer is Novartis.
The recall was initiated due to cGMP deviations involving temperature abuse during manufacturing or storage.
Product distributed to customers between June 1 and September 30, 2021 is affected. McKesson Medical-Surgical notes that specific lot numbers cannot be identified by distributor, so customers should use their own records to determine if they received recalled product during this timeframe and whether any remains in inventory.
Customers and healthcare providers with questions should contact Sedgwick. Patients using this medication should consult their healthcare provider regarding this recall.
The recalled product
- Product
- TOBRADEX (TOBRAMYCIN AND DEXAMETHASONE)
- Brand
- TOBRADEX
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Category
- Drug — Ophthalmic / Prescription
- Hazard
- temperature-abuse
- cGMP-deviation
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27